HUE064731T2 - 5-Metil-(6S)-tetrahidrofolsavat és L-leucin-etilésztert tartalmazó kristályos só - Google Patents

5-Metil-(6S)-tetrahidrofolsavat és L-leucin-etilésztert tartalmazó kristályos só

Info

Publication number
HUE064731T2
HUE064731T2 HUE19737496A HUE19737496A HUE064731T2 HU E064731 T2 HUE064731 T2 HU E064731T2 HU E19737496 A HUE19737496 A HU E19737496A HU E19737496 A HUE19737496 A HU E19737496A HU E064731 T2 HUE064731 T2 HU E064731T2
Authority
HU
Hungary
Prior art keywords
methyl
ethyl ester
tetrahydrofolic acid
crystalline salts
leucine ethyl
Prior art date
Application number
HUE19737496A
Other languages
English (en)
Inventor
Rudolf Moser
Viola Groehn
Stamm Ruth Boehni
Fritz Blatter
Martin Szelagiewicz
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of HUE064731T2 publication Critical patent/HUE064731T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • C07D475/02Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
HUE19737496A 2018-07-06 2019-07-02 5-Metil-(6S)-tetrahidrofolsavat és L-leucin-etilésztert tartalmazó kristályos só HUE064731T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18182279 2018-07-06

Publications (1)

Publication Number Publication Date
HUE064731T2 true HUE064731T2 (hu) 2024-04-28

Family

ID=62874793

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE19737496A HUE064731T2 (hu) 2018-07-06 2019-07-02 5-Metil-(6S)-tetrahidrofolsavat és L-leucin-etilésztert tartalmazó kristályos só

Country Status (12)

Country Link
US (1) US11925644B2 (hu)
EP (1) EP3817813B1 (hu)
JP (1) JP7473526B2 (hu)
CN (1) CN112312968A (hu)
AU (1) AU2019297312A1 (hu)
CA (1) CA3105545A1 (hu)
DK (1) DK3817813T3 (hu)
ES (1) ES2966940T3 (hu)
FI (1) FI3817813T3 (hu)
HU (1) HUE064731T2 (hu)
PT (1) PT3817813T (hu)
WO (1) WO2020007839A1 (hu)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112125906A (zh) * 2020-10-27 2020-12-25 哈尔滨理工大学 S-5-甲基四氢叶酸氨基酸酯盐及其合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH693905A5 (de) 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
CN103664945B (zh) * 2012-09-07 2016-01-20 南京莱因医药科技有限公司 L-5-甲基四氢叶酸氨基酸盐的制备方法
US20160207925A1 (en) 2013-12-31 2016-07-21 Gianni Fracchia L-methylfolate salt preparations, medicaments, and nutritional supplements comprising such salts thereof
CN107304212A (zh) * 2016-04-21 2017-10-31 常州爱诺新睿医药技术有限公司 一种无定型l-5-甲基四氢叶酸氨基酸盐及其制备方法

Also Published As

Publication number Publication date
ES2966940T3 (es) 2024-04-25
WO2020007839A1 (en) 2020-01-09
US11925644B2 (en) 2024-03-12
EP3817813A1 (en) 2021-05-12
US20210283136A1 (en) 2021-09-16
AU2019297312A1 (en) 2021-03-04
EP3817813B1 (en) 2023-09-20
JP2021529802A (ja) 2021-11-04
PT3817813T (pt) 2023-12-22
CN112312968A (zh) 2021-02-02
JP7473526B2 (ja) 2024-04-23
CA3105545A1 (en) 2020-01-09
DK3817813T3 (da) 2023-12-11
FI3817813T3 (fi) 2023-12-15

Similar Documents

Publication Publication Date Title
ZA201804870B (en) Acid addition salts of piperazine derivatives
IL279101A (en) Salts of spiafatrin are accepted in pharmacies
MX2018003649A (es) Metodos e intermedios para la preparacion de derivados de acido biliar.
IL273579A (en) Salts of pyrrolothrizine compounds used as tem inhibitors.
IL280841A (en) Succinate and fumarate acid addition salts of piperazine derivatives used as glycosidase inhibitors
EP3853852A4 (en) DYNAMIC CONFIGURATION OF MEMORY SYNCHRONIZATION PARAMETERS
EP3408254A4 (en) SALTS OF 5-AMINOLÄVULINIC ACID AND DERIVATIVES
EP3790881A4 (en) LONG-ACTING INJECTABLE FORMULATIONS AND CRYSTALLINE FORMS OF BUPRENORPHINE DERIVATIVES
PT3817813T (pt) Sais cristalinos de ácido 5metil-(6s)-tetra.hidrofólico e de éster etílico de l-leucina
MX2019003684A (es) Formas cristalinas de un derivado de acido biliar.
HUE064746T2 (hu) 5-Metil-(6S)-tetrahidrofolsav és l-valin-etilészter kristályos sói
HUE064730T2 (hu) 5-Metil-(6S)-tetrahidrofolsavat és L-izoleucin-etilésztert tartalmazó kristályos só
IL269073A (en) Crystalline forms of obeticholic acid
EP3445751A4 (en) NEW POLYMORPHE FORM OF CRYSTALLINE ROSUVASTATIN CALCIUM AND NEW PROCESSES FOR CRYSTALLINE AND AMORPHIC ROSUVASTATIN CALCIUM
PL3818048T3 (pl) Krystaliczna sól zawierająca kwas 5-metylo-(6s)-tetrahydrofoliowy i 4-(2-hydroksyetylo)-morfolinę
IL274758A (en) Crystalline forms of praquinostat
SG11202108905UA (en) Crystalline form of an avibactam derivative
EP3896063A4 (en) SYK INHIBITOR SALT AND CORRESPONDING CRYSTALLINE FORM
GB201912411D0 (en) Crystalline forms of ivosidenib
ZA202008062B (en) Pharmaceutically acceptable salts of sepiapterin
EP3887367A4 (en) CRYSTALLINE SALTS OF CORYDALMINE
EP4069674A4 (en) CRYSTALLINE FORM I OF BUCILLAMIN
EP3781155A4 (en) MEGLUMINAL SALT OF THIENOPYRIMIDINES
EP3837356A4 (en) AMORPHIC AND CRYSTALLINE FORMS OF VALBENAZINE SALT
GB202009218D0 (en) Crystalline forms of entrectinib